LENSAR Declares Incentive Grants Beneath Nasdaq Itemizing Rule 5635(c)(4) By Investing.com

ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) — LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Firm) immediately introduced {that a} majority of the impartial members of the LENSAR Board of Administrators have granted to 3 newly employed inventory choices for non-executive workers to buy a complete of 1,650 widespread shares of the Firm. The choices had been granted on January 2, 2025, as a major profit to every worker getting into employment with the Firm. The choices had been granted pursuant to Nasdaq Itemizing Rule 5635(c)(4).

The choices have an train worth of $8.69 per share, which corresponds to the closing worth of the Firm’s widespread inventory on the grant date. Choices vest as much as 25% of the entire grant quantity beginning on the primary anniversary of the grant date and in thirty-six considerably equal month-to-month installments thereafter, topic to the brand new worker remaining inside the firm. the corporate. Every inventory possibility has a time period of 10 years. The choices are topic to the phrases and circumstances of LENSAR’s 2024 Employment Incentive Plan and a inventory possibility settlement masking the grant.

About LENSAR

LENSAR is a commercial-stage medical machine firm centered on the design, growth and commercialization of superior methods for cataract therapy and astigmatism administration as an integral side of the process. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, extremely ergonomic system utilizing a particularly quick dual-modality laser and integrating AI into imaging and proprietary software program. ALLY is designed to remodel high-end cataract surgical procedure utilizing LENSAR’s superior robotic applied sciences with the flexibility to carry out the complete process in a sterile working room or in-office working theater, offering operational effectivity and decreasing overhead prices. ALLY contains LENSAR’s proprietary Streamline ® software program know-how, designed to information surgeons towards higher outcomes.

Supply: LENSAR, Inc.